OROlivier Rigal

Olivier Rigal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olivier Rigal has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Change in the value of work after breast cancer: evidence from a prospective cohort

    by Elsa Caumette, Antonio Di Meglio, Inès Vaz-Luis, Cécile Charles, Julie Havas, Garazi Ruiz de Azua, Elise Martin, Laurence Vanlemmens, Suzette Delaloge, Sibille Everhard, et al.

    Background Return to work (RTW) after cancer can be modulated by psychosocial factors, including a reordering of one’s life values, with more emphasis on private life than work-life. This change in patients’ outlook on work-life is however poorly understood. Methods We used data from a French cohort (CANTO, NCT01993498) of women diagnosed with stage I–III primary breast cancer (BC) prospectively assessing life priorities between work and private life at diagnosis and 2 years after diagnosis. We identified women who reported a shift in life values toward private life, and we investigated the clinical, demographic, work-related, and psychosocial determinants of this change using logistic regressions. Results Overall, 46% (N = 1097) of the women had reordered their life priorities toward private life 2 years after diagnosis. The factors positively associated with this shift included being diagnosed with stage III BC, perceiving one’s job as not very interesting, being an employee/clerk (vs. executive occupation), perceiving no support from the supervisor at baseline, perceiving negative interferences of cancer in daily life, and perceiving a positive impact from experiencing cancer. Depressive symptoms were negatively associated with this shift. Conclusion After BC, there seems to be an important reordering of life values, with more emphasis on private life. This change is influenced by clinical determinants, but also by work-related and psychosocial factors. Implications for Cancer Survivors Stakeholders should consider this change in a patient’s outlook on work-life as much as the classical physical late effects when designing post-BC programs to support RTW.


  • Open Access

    Prospective Evaluation of Sarcopenia in Head and Neck Cancer Patients Treated with Radiotherapy or Radiochemotherapy

    by Sébastien Thureau, Lucie Lebret, Justine Lequesne, Marine Cabourg, Simon Dandoy, Céline Gouley, Laureline Lefebvre, Romain Mallet, Sorina-Dana Mihailescu, Cristian Moldovan, et al.

    Highlights: Sarcopenia is frequent in patients treated with radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinomas. Sarcopenia is associated with poor disease-free survival and overall survival outcomes. Sarcopenia is not associated with a higher rate of treatment-related toxicity. Background: Sarcopenia occurs frequently with the diagnosis of head and neck squamous cell carcinoma (HNSCC). We aimed to assess the impact of sarcopenia on survival among HNSCC patients treated with radiotherapy (RT) or radiochemotherapy (RTCT). Methods: Patients treated between 2014 and 2018 by RT or RTCT with curative intent were prospectively included (NCT02900963). Optimal nutritional support follow-up, including weekly consultation with a dietician and an oncologist and daily weight monitoring, was performed. Sarcopenia was determined by measuring the skeletal muscles at the L3 vertebra on the planning CT scan for radiotherapy. For each treatment group (RT or RTCT), we assessed the prognostic value of sarcopenia for disease-free survival (DFS) and overall survival (OS) and its impact on treatment-related toxicity. Results: Two hundred forty-three HNSCC patients were included: 116 were treated by RT and 127 were treated by RTCT. Before radiotherapy, eight (3.3%) patients were considered malnourished according to albumin, whereas 88 (36.7%) patients were sarcopenic. Overall, sarcopenia was associated with OS and DFS in a multivariate analysis (HR 1.9 [1.1–3.25] and 1.7 [1.06–2.71], respectively). It was similar for patients treated with RT (HR 2.49 [1.26–4.9] for DFS and 2.24 [1.03–4.86] for OS), whereas for patients treated with RTCT sarcopenia was significantly associated with OS and DFS in univariate analysis only. Sarcopenia was not related to higher treatment-related toxicity. Conclusions: Pretherapeutic sarcopenia remains frequent and predicts OS and DFS for non-frail patients treated with curative intent and adequate nutritional support.


  • Baseline cognitive functions among elderly patients with localised breast cancer

    by Marie Lange, Bénédicte Giffard, Sabine Noal, Olivier Rigal, Jean-Emmanuel Kurtz, Natacha Heutte, Christelle Lévy, Djelila Allouache, Chantal Rieux, Johan Le Fel, et al.


  • Cognitive dysfunctions in elderly cancer patients: A new challenge for oncologists

    by Marie Lange, Olivier Rigal, Bénédicte Clarisse, Bénédicte Giffard, Emmanuel Sevin, Marie Barillet, Francis Eustache, Florence Joly


  • La place des proches en onco-hématologie, utopie ou réalité ?

    by A. Altmeyer, C. Bauchetet, F. Victoire-Feron, C. Guillemet, O. Rigal

    L’annonce d’un cancer s’accompagne de bouleversements majeurs, non seulement pour les patients mais, également, pour leur entourage proche. Il n’existe pas de définition universelle pour « les proches », il peut s’agir aussi bien du conjoint, de partenaires, des enfants, de parents ou d’amis. Ils sont très fréquemment la première source de soutien, et leur rôle évolue tout au long de la maladie en fonction des besoins du patient. Les proches sont amenés à collaborer étroitement avec les équipes soignantes, ils contribuent aux soins et à l’amélioration de la qualité de vie des patients. Ils négligent néanmoins fréquemment leur propre bien-être, que ce soit au niveau psychologique, physique, social, financier ou spirituel. Cet article a pour objectif de décrire le rôle des proches, les retentissements possibles sur leur propre qualité de vie, de répertorier et de proposer des soutiens pour leur venir en aide dans l’accompagnement auprès des patients. A cancer diagnosis has a significant impact not only on the patients, but also on their caregivers. There is no universal definition for the term “caregivers” and it may include spouses, partners, children, relatives, or friends. Caregivers are often the primary source of support and their role changes as the patient’s needs change. Caregivers work with the health care team and have an important role in improving the patient’s health quality of life. But caregivers often neglect their own well-being, including psychological, physical, social, financial, or spiritual issues. This article will attempt to provide an understanding of the multifaceted role of caregivers in cancer care, describe the impact of this role on the caregiver’s quality of life, describe interventions, and formulate proposals for providing support to non-medical persons caring for patients with cancer.


    • 1 December 2013
      • Vol. 33  (12) , 5655-62

    A higher body mass index and fat mass are factors predictive of docetaxel dose intensity.

    by Sophie Gouérant, Marianne Leheurteur, Maher Chaker, Romain Modzelewski, Olivier Rigal, Corinne Veyret, Géraldine Lauridant, Florian Clatot

    Few data are published on docetaxel toxicity in obese patients. All obese patients (n=100) treated for early breast cancer during three consecutive years at our Institution, were retrospectively investigated. The same number of non-obese patients was randomly selected and used as controls. We assessed the factors predictive of the relative dose intesity (RDI) reduction, including body composition. A total of 18% (n=18) of obese patients and 5% (n=5) of non-obese patients required reduction of docetaxel RDI due to toxicity (p=0.008). In a multivariate analysis, body mass index (BMI) and age were predictive of a reduction in RDI. Among the 89 patients with a determination of body composition, patients with a higher fat mass more frequently had a reduction in docetaxel RDI (p=0.002). In multivariate analysis, fat mass was the only independent factor predictive of a reduction in docetaxel RDI. Obese patients treated for early breast cancer more frequently required a reduction in docetaxel RDI. Fat mass seems to be the best factor predictive of a reduction in docetaxel RDI.